Business Wire (Wed, 27-May 4:34 PM ET)
Business Wire (Tue, 26-May 4:05 PM ET)
ICON expands US early phase research capabilities with new clinic and outpatient centres
Business Wire (Wed, 13-May 8:00 AM ET)
Globe Newswire (Tue, 5-May 8:00 AM ET)
ICON Audit Committee Finds Revenue Overstatement Below 2%—Restatement Process Nears Conclusion
Market Chameleon (Wed, 29-Apr 3:58 AM ET)
Business Wire (Wed, 29-Apr 7:00 AM ET)
ICON and Advarra Introduce New 'Research-Ready,' Connected Site Network Model
Business Wire (Tue, 24-Mar 8:00 AM ET)
Globe Newswire (Mon, 16-Mar 11:02 AM ET)
Icon Public Limited Company Investigated by the Portnoy Law Firm
Globe Newswire (Wed, 11-Mar 9:00 AM ET)
Icon Limited Public Company. Investigated by the Portnoy Law Firm
Globe Newswire (Wed, 11-Mar 9:00 AM ET)
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Icon PLC - trades on the NASDAQ stock market under the symbol ICLR.
As of June 9, 2026, ICLR stock price declined to $151.82 with 1,125,958 million shares trading.
ICLR has a beta of 2.08, meaning it tends to be more sensitive to market movements. ICLR has a correlation of 0.11 to the broad based SPY ETF.
ICLR has a market cap of $11.59 billion. This is considered a Large Cap stock.
Last quarter Icon PLC - reported $2 billion in Revenue and $2.52 earnings per share. This beat revenue expectation by $137 million and missed earnings estimates by -$.53.
In the last 3 years, ICLR traded as high as $347.72 and as low as $66.57.
The top ETF exchange traded funds that ICLR belongs to (by Net Assets): DFSV, PIEQ, DSTL, SPDW, DFAT.
ICLR has underperformed the market in the last year with a return of +9.1%, while SPY returned +24.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ICLR shares. However, ICLR has outperformed the market in the last 3 month and 2 week periods, returning +41.6% and +30.0%, while SPY returned +9.9% and -1.2%, respectively. This indicates ICLR has been having a stronger performance recently.
ICLR support price is $147.34 and resistance is $157.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICLR shares will trade within this expected range on the day.
